| Previous Close | 0.9800 |
| Open | 0.9800 |
| Bid | 0.8800 x 500 |
| Ask | 1.0800 x 3000 |
| Day's Range | 0.9600 - 0.9900 |
| 52 Week Range | 0.8000 - 1.4200 |
| Volume | 412,534 |
| Avg. Volume | 366,006 |
| Market Cap | 88.36M |
| Beta | -0.05 |
| PE Ratio (TTM) | -3.19 |
| EPS (TTM) | -0.3 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.33 |
- Zacks•2 days ago
BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.
- Zacks•12 days ago
BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
- PR Newswire•13 days ago
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1b/2 study for BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech's anti-PDL1 cancer immunotherapy agent, evaluating the combination in metastatic pancreatic ductal adenocarcinoma. Up to 40 patients are planned to be enrolled in this Phase 1b/2, multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab. Initially, patients will receive BL-8040 injections as priming monotherapy for five consecutive days, after which, from day 8, they will receive both BL-8040 and atezolizumab, and continue with multiple treatment cycles for up to two years or until disease progression, clinical deterioration or unacceptable toxicity.
